Center for Biomolecular and Tissue Engineering Center for Biomolecular and Tissue Engineering
Pratt School of Engineering
Duke University

 HOME > pratt > CBTE    Search Help Login pdf version printable version 

Publications [#64520] of Bruce M. Klitzman

Papers Published

  1. Olbrich, K.C. and Meade, R.A. and Bruno, W. and Sundin, B.M. and Heller, L. and Erdmann, D. and Levin, L.S. and Klitzman, B., Tempostatin [trademark] (halofuginone) inhibits collagen deposition in fibrous capsules, Transactions - 7th World Biomaterials Congress (2004), pp. 294 -, Sydney, Australia
    (last updated on 2007/04/15)

    A study proposed to see the effectiveness of a collagen type I synthesis inhibitor, Tempostatin [trademark] (Halofuginone), at inhibiting collagen deposition around implanted materials was discussed. The data indicated that halofuginone was effective at inhibiting the deposition of collagen within the capsule that formed around the implanted silicone. It was also indicated that halofuginone inhibited collagen synthesis by inhibiting TGF-β activity. The presence of TGF-beta in the peri-implant space suggested that halofuginone treatment may be an effective method for minimizing fibrous capsule formation around implants.

    Fibers;Implants (surgical);Enzyme inhibition;Synthesis (chemical);Colorimetry;Blood;Chromophores;Morphology;

Duke University * Pratt * CBTE * Reload * Login